[1] |
Moy AP, Murali M, Kroshinsky D, et al. Immunologic overlap of helper T⁃cell subtypes 17 and 22 in erythrodermic psoriasis and atopic dermatitis[J]. JAMA Dermatol, 2015,151(7):753⁃760. doi: 10.1001/jamadermatol.2015.2.
|
[2] |
Snoeck R, Andrei G, De Clercq E. Novel agents for the therapy of varicella⁃zoster virus infections[J]. Expert Opin Investig Drugs, 2000,9(8):1743⁃1751. doi: 10.1517/13543784.9.8.1743.
|
[3] |
Wagner JN, Leibetseder A, Troescher A, et al. Efficacy and safety of intravenous immunoglobulins for the treatment of viral encephalitis: a systematic literature review[J]. J Neurol, 2022,269(2):712⁃724. doi: 10.1007/s00415⁃021⁃10494⁃w.
|
[4] |
Mohammadzadeh I, Noei S, Babazadeh K, et al. Comparison of early and late intravenous gamma globulin treatment of Kawasaki disease on fever and cardiovascular complications[J]. Caspian J Intern Med, 2016,7(3):211⁃216.
|
[5] |
Wu KK, Lee MP, Lee EB, et al. Risk of herpes zoster with IL⁃17 inhibitor therapy for psoriasis and other inflammatory conditions[J]. J Dermatolog Treat, 2020,31(4):359⁃365. doi: 10.1080/09546634.2019.1597246.
|
[6] |
Lønnberg AS, Zachariae C, Skov L. Targeting of interleukin⁃17 in the treatment of psoriasis[J]. Clin Cosmet Investig Dermatol, 2014,7:251⁃259. doi: 10.2147/CCID.S67534.
|
[7] |
Lo Y, Tsai TF. Updates on the Treatment of Erythrodermic Psoriasis[J]. Psoriasis (Auckl), 2021,11:59⁃73. doi: 10.2147/PTT.S288345.
|
[8] |
Mateu⁃Puchades A, Santos⁃Alarcón S, Martorell⁃Calatayud A, et al. Erythrodermic psoriasis and secukinumab: our clinical experience[J]. Dermatol Ther, 2018,31(4):e12607. doi: 10.1111/dth.12607.
|
[9] |
Lo Y, Tsai TF. Clinical experience of ixekizumab in the treatment of patients with history of chronic erythrodermic psoriasis who failed secukinumab: a case series[J]. Br J Dermatol, 2019,181(5):1106⁃1107. doi: 10.1111/bjd.18174.
|